# OnCo record nct04093167 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04093167/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04093167", "NCT04093167" ;
  schema:name "Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer"@en ;
  schema:description "A phase 2/3 trial of pembrolizumab in lung cancer, run by Canadian Cancer Trials Group, active but no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04093167/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04093167> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "2/3" ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/cctg/> .